TY - JOUR
T1 - Functional clinical outcomes in multiple sclerosis
T2 - Current status and future prospects
AU - Karabudak, Rana
AU - Dahdaleh, Maurice
AU - Aljumah, Mohammed
AU - Alroughani, Raed
AU - Alsharoqi, I. Ahmed
AU - Altahan, Abdulrahman M.
AU - Bohlega, Saeed A.
AU - Daif, Abdulkader
AU - Deleu, Dirk
AU - Amous, Amer
AU - Inshasi, Jihad S.
AU - Rieckmann, Peter
AU - Sahraian, Mohammed A.
AU - Yamout, Bassem I.
N1 - Publisher Copyright:
© 2015 Elsevier B.V.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - For decades, the Expanded Disability Status Scale (EDSS) has been the principal measure of disability in clinical trials in patients with multiple sclerosis (MS) and in clinical practice. However, this test is dominated by effects on ambulation. Composite endpoints may provide a more sensitive measure of MS-related disability through the measurement of additional neurological functions. The MS Functional Composite (MSFC) includes a walking test (25-ft walk) plus tests of upper extremity dexterity (9-hole peg test) and cognitive function (Paced Auditory serial Addition test [PASAT]). Replacing PASAT with the Symbol Digit Modality test, a more sensitive test preferred by patients, may improve the clinical utility of the MSFC. In addition, disease-specific measures of QoL may be used alongside the MSFC (which does not include measurement of QoL). Clinical data suggest that disease-modifying therapies may delay or prevent relapse, and better composite measures will be valuable in the assessment of disease activity-free status in people with MS.
AB - For decades, the Expanded Disability Status Scale (EDSS) has been the principal measure of disability in clinical trials in patients with multiple sclerosis (MS) and in clinical practice. However, this test is dominated by effects on ambulation. Composite endpoints may provide a more sensitive measure of MS-related disability through the measurement of additional neurological functions. The MS Functional Composite (MSFC) includes a walking test (25-ft walk) plus tests of upper extremity dexterity (9-hole peg test) and cognitive function (Paced Auditory serial Addition test [PASAT]). Replacing PASAT with the Symbol Digit Modality test, a more sensitive test preferred by patients, may improve the clinical utility of the MSFC. In addition, disease-specific measures of QoL may be used alongside the MSFC (which does not include measurement of QoL). Clinical data suggest that disease-modifying therapies may delay or prevent relapse, and better composite measures will be valuable in the assessment of disease activity-free status in people with MS.
KW - Clinical outcome measures
KW - Clinical trials
KW - Disease-modifying therapies
KW - Multiple sclerosis
UR - https://www.scopus.com/pages/publications/84930180445
U2 - 10.1016/j.msard.2015.03.004
DO - 10.1016/j.msard.2015.03.004
M3 - Review article
C2 - 26008936
AN - SCOPUS:84930180445
SN - 2211-0348
VL - 4
SP - 192
EP - 201
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
IS - 3
ER -